Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Two approaches to discovering and developing new drugs for Chagas disease McKerrow JH; Doyle PS; Engel JC; Podust LM; Robertson SA; Ferreira R; Saxton T; Arkin M; Kerr ID; Brinen LS; Craik CSMem Inst Oswaldo Cruz 2009[Jul]; 104 Suppl 1 (0 1): 263-9This review will focus on two general approaches carried out at the Sandler Center, University of California, San Francisco, to address the challenge of developing new drugs for the treatment of Chagas disease. The first approach is target-based drug discovery, and two specific targets, cytochrome P450 CYP51 and cruzain (aka cruzipain), are discussed. A 'proof of concept' molecule, the vinyl sulfone inhibitor K777, is now a clinical candidate. The preclinical assessment compliance for filing as an Investigational New Drug with the United States Food and Drug Administration (FDA) is presented, and an outline of potential clinical trials is given. The second approach to identifying new drug leads is parasite phenotypic screens in culture. The development of an assay allowing high throughput screening of Trypanosoma cruzi amastigotes in skeletal muscle cells is presented. This screen has the advantage of not requiring specific strains of parasites, so it could be used with field isolates, drug resistant strains or laboratory strains. It is optimized for robotic liquid handling and has been validated through a screen of a library of FDA-approved drugs identifying 65 hits.|*Drug Design[MESH]|Animals[MESH]|Chagas Disease/*drug therapy[MESH]|Cysteine Endopeptidases[MESH]|Cysteine Proteinase Inhibitors/*therapeutic use[MESH]|Cytochrome P-450 Enzyme Inhibitors[MESH]|Cytochrome P-450 Enzyme System[MESH]|Dipeptides/*therapeutic use[MESH]|Humans[MESH]|Phenylalanine/analogs & derivatives[MESH]|Piperazines[MESH]|Protozoan Proteins/antagonists & inhibitors[MESH]|Tosyl Compounds[MESH]|Trypanocidal Agents/*therapeutic use[MESH]|United States[MESH]|United States Food and Drug Administration[MESH]|Vinyl Compounds/*therapeutic use[MESH] |